Medtronic PLC (MDT, Financial) files its latest 10-K with SEC for the fiscal year ended on April 30, 2018. Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments. Medtronic PLC has a market cap of $116.87 billion; its shares were traded at around $86.30 with a P/E ratio of 38.19 and P/S ratio of 3.93. The dividend yield of Medtronic PLC stocks is 2.13%. Medtronic PLC had annual average EBITDA growth of 6.90% over the past ten years. GuruFocus rated Medtronic PLC the business predictability rank of 4.5-star.
For the last quarter Medtronic PLC reported a revenue of $8.1 billion, compared with the revenue of $7.9 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $30 billion, an increase of 0.8% from last year. For the last five years Medtronic PLC had an average revenue growth rate of 15.3% a year.
The reported diluted earnings per share was $2.27 for the year, a decline of 21.5% from the previous year. Over the last five years Medtronic PLC had an average EPS decline of 5.8% a year. The Medtronic PLC had a decent operating margin of 21.18%, compared with the operating margin of 21.25% a year before. The 10-year historical median operating margin of Medtronic PLC is 25.72%. The profitability rank of the company is 9 (out of 10).
At the end of the fiscal year, Medtronic PLC has the cash and cash equivalents of $3.7 billion, compared with $5 billion in the previous year. The long term debt was $23.7 billion, compared with $25.9 billion in the previous year. The interest coverage to the debt is 5.5. Medtronic PLC has a financial strength rank of 6 (out of 10).
At the current stock price of $86.30, Medtronic PLC is traded at 11.4% premium to its historical median P/S valuation band of $77.44. The P/S ratio of the stock is 3.93, while the historical median P/S ratio is 3.53. The intrinsic value of the stock is $24.19 a share, according to GuruFocus DCF Calculator. The stock lost 0.73% during the past 12 months.
Directors and Officers Recent Trades:
- SVP General Counsel & Corp Sec Bradley E Lerman sold 8,910 shares of MDT stock on 06/11/2018 at the average price of $86.82. The price of the stock has decreased by 0.6% since.
- SVP & Chief Medical & Science Richard Kuntz sold 11,500 shares of MDT stock on 06/08/2018 at the average price of $87.13. The price of the stock has decreased by 0.95% since.
For the complete 20-year historical financial data of MDT, click here.
